A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of Budigalimab and/or ABBV-382 in People Living With HIV on Stable Antiretroviral Therapy Undergoing Analytical Treatment Interruption

Protocol No
INF-ABBVIE-M19-965-HIV
Phase
II
Summary

This project is being done to learn if budigalimab and/or ABBV-382 can help the body control the HIV viral load after ART has been stopped.

Description
Abbvie M19-965 HIV study
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL